The Role of Data in Healthcare Mergers and Acquisitions

Data streamlines due diligence. Thus, in healthcare mergers and acquisitions (M&A), organizations have stopped relying on gut instinct. They say no to presumptions because boardroom discussions go nowhere without healthcare data insights. That is understandable.

Stakeholders in this industry can be maintaining thin margins. Still, they must keep moving forward with mergers. But without concrete data, that will not be possible for them. Besides, there are compliance complications necessitating due diligence. This post will highlight the role of data in healthcare M&A transactions.

Why Data Has Become Central to Healthcare Mergers and Acquisitions

1. Nobody Can Navigate the Complex Healthcare Market on Their Own

Healthcare was never a uniform industry. It has all kinds of players, including:

• Hospitals and physician groups
• Health insurance payers
• Medical device companies
• Pharmaceutical firms
• Digital health platforms.

For each of these stakeholders, financial, clinical, and regulatory risk profiles drastically differ. How does this factor into PE firms’ decision-making? Well, a transaction that appears sound on the surface during the initial assessments can actually be misleading.

In other words, lies will go unnoticed.

Think of undisclosed liabilities. Are there any payor contract inconsistencies or electronic health record (EHR) incompatibilities? Investors, PE teams, and leaders must cross-examine that. Healthcare data systems can also help them in this endeavor.

2. Rising Deal Volumes and Competitive Pressure Are More Intense than Ever

Healthcare M&A activity is growing, with many private equity firms taking an interest in those transactions. Therefore, modern health systems and strategic acquirers must compete. Regardless of a shrinking pool of high-quality targets, they must move forward. Yes, competition compresses timelines. That is why healthcare market research services are valuable. Today, firms can tap into them and successfully deploy analytical tools.

Definitive Healthcare, IQVIA, and PitchBook already lead the race. They know the best ways to help PE teams gain a decisive edge. For instance, from identifying targets faster to preventing costly decisions, they perform multiple functions.

3. Regulatory Scrutiny and Compliance Demands Are Only Growing

It is not just the US Federal Trade Commission (FTC) & the Department of Justice (DOJ) that scrutinize large healthcare deals. More nations are considering stricter frameworks for health and life science stakeholders. From an M&A-favoring position, antitrust reviews that require extensive market concentration data also call for comprehensive, auditable record-keeping.

As of now, organizations must submit Herfindahl-Hirschman Index (HHI) calculations. After all, the policymakers and patients are clearly not fans of monopolies. HHI helps estimate and prevent those situations.

Additionally, patient volume analyses are also crucial to the regulatory bodies. So, it is best for PE firms, especially healthcare acquirers and insurers, to be ready with the necessary reports early on.

Which Data Sources Are Essential for Healthcare M&A Deal Evaluation

1. Claims and Clinical Data

Medical claims data enhances healthcare M&A intelligence. First, it reveals a target organization’s patient volume trends. There will be detailed discussions concerning service line performance and payor mix. So, claims and clinical trial data will be central.

As a result, platforms like Clarify Health and Komodo Health aggregate de-identified claims data. The process also preserves the anonymity of care beneficiaries. That approach aligns well with HIPAA, a personally identifiable information (PII) governance law in the US.

Through such methods, benchmarking clinical outcomes gets easier. Acquirers using mergers & acquisitions support services can use such information to validate a target’s revenue projections. They can also identify reimbursement risks.

Yes, it is exactly as powerful as it sounds.

2. Financial and Operational Data

Financial data, especially in healthcare mergers and acquisitions, must go beyond the typical income statement. For example, truly sophisticated buyers will examine days sales outstanding (DSO), cost per adjusted discharge, and staff-to-patient ratios. They will also assess the supply chain costs.

Similarly, operational data that an enterprise resource planning (ERP) system offers (like Oracle Health and SAP Healthcare) provides granular insight into efficiency. This data helps buyers estimate post-merger advantages with greater precision.

3. Market and Competitive Intelligence

Market data reveals where a target fits. Buyer firms can use healthcare market research and insights to map referral networks. They can also assess geographic reach or evaluate demographic trends in target markets instead.

Think of tools like Sg2 and Trella Health. They provide physician referral analytics, including market share data. This healthcare M&A intelligence determines whether an acquisition expands market access or just adds another overhead.

Data Analytics in the Due Diligence for Healthcare Mergers and Acquisitions

What is Quantitative Due Diligence?

Traditional due diligence focuses on audited financials. It also extends to legal disclosures. Now, quantitative due diligence thrives due to the progress of predictive analytics and statistical modeling. Therefore, buyers can quickly model revenue projections. They can conduct tests concerning multiple scenarios using tools like Tableau.

Power BI and Python-based analytics are also available for healthcare M&A intelligence purposes. For instance, you can use them to stress-test assumptions around payor contract renewals. How do physician retention rates fluctuate? What about volume ramp-ups? Answering these questions gets less overwhelming thanks to quantitative due diligence.

How Operational and Clinical Quality Assessment Help PE Teams

Buyers assess clinical quality metrics, which constitute most of the operational due diligence. Key indicators include hospital consumer assessment of healthcare providers and systems (HCAHPS) scores. Similarly, readmission rates and infection control data insights matter a lot.

Notably, the Centers for Medicare and Medicaid Services (CMS) publicly reports many of these metrics. In short, it is essential to admit that the organizations with poor clinical outcomes will carry hidden liability risks. Data identifies these before the healthcare M&A transaction closes.

Conclusion

Healthcare M&A success primarily depends on data quality. With analytical rigor, there must be timely availability when it comes to getting, visualizing, and cleaning insights. Thus, private equity firms, investment banks, and healthcare leaders must be vigilant.

Think of ways in which data insights ensure every stage of a transaction has fewer risks and better deal outcomes.

From claims analysis to clinical quality benchmarks, no matter the task, the significance of data is evident. Indeed, each data point sharpens decision-making for major and minor healthcare industry stakeholders. Today, in this sector, the best healthcare M&A deals will inevitably go to those who ask the right questions, trust the right data, and form the right fintech partnerships.